Mar 3, 2020
Analysis of the PPMI dataset has shown that compared to people with sporadic forms of Parkinson’s, newly diagnosed people carrying GBA mutations are less severely impaired, and those with LRRK2 mutations appear more mildly affected.
Dec 20, 2019
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
Jun 19, 2019
Serotonin changes seen before dopamine changes in people with A53T SNCA mutation.
Jan 28, 2015
The more a placebo costs the greater the effect.